Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02569476
Title BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications

leukemia

B-cell lymphoma

Therapies

Obinutuzumab + Zanubrutinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Florida Cancer Specialists Fort Myers Florida 33916 United States Details
Florida Cancer Specialists Saint Petersburg Florida 33705 United States Details
Tennessee Oncology, PLLC - Nashville Nashville Tennessee 37203 United States Details
Border Medical Oncology Albury New South Wales 2640 Australia Details
St George Hospital Kogarah New South Wales 2217 Australia Details
Brisbane Clinic for Lymphoma, Myeloma and Leukaemia Greenslopes Queensland 4120 Australia Details
Ashford Cancer Centre Research Kurralta Park South Australia 5037 Australia Details
St Vincent's Hospital Melbourne East Melbourne Victoria 3002 Australia Details
University Hospital Geelong Geelong Victoria 3220 Australia Details
St Frances Xavier Cabrini Hospital Malvern Victoria 3144 Australia Details
The Alfred Hospital Melbourne Victoria 3181 Australia Details
Royal Perth Hospital Perth Western Australia 6000 Australia Details
Severance Hospital, Yonsei University Seoul 03722 Korea, Republic of Details
Asan Medical Center Seoul 05505 Korea, Republic of Details
Samsung Medical Center Seoul 06351 Korea, Republic of Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field